Brett Jackson

Counsel

Brett Jackson

Boston

+1 617 570 1657

Brett Jackson is counsel in the firm’s Business Law department and a member of its nationally recognized Technology and Life Sciences group, including its market leading Technology M&A practice. With extensive experience representing startups and established public and private companies in the software, technology, and life sciences sectors, Brett guides clients through all stages of their business life cycles. His expertise encompasses pre-incorporation planning, venture capital and growth equity financing, mergers and acquisitions, secondary transactions, and other strategic corporate matters. Additionally, Brett advises venture capital and private equity funds focused on technology and life sciences investments. Since joining Goodwin in 2018, Brett has demonstrated a commitment to providing practical, tailored legal solutions that drive growth and innovation for his clients.

Representative Matters

Empower Semiconductor in its $140 million Series D financing
General Catalyst Partners in venture financing matters
Scrunch AI in its Series A Financing
Videahealth in its $40 million Series B financing
Labviva in its $25 million Series B financing
Cardflight in its growth equity investment from WestView Capital Partners
Starburst Data, an enterprise database software company, as outside general counsel and in its equity financings
Placemakr, a flexible-use multifamily and hospitality operator in its equity financings
An online banking and payments company in its equity financings, including its $131 million Series C financing
Reggora, an appraisal technology company, as outside general counsel and in its equity financings
EQRX in its equity financings, including a $500 million Series B financing
OpenExchange, a provider of video and virtual event solutions, as outside general counsel and in its equity financings

Quavo Fraud & Disputes in its investment by Spectrum Equity
Interactions Corp. in its sale to SoundHound AI
Autobooks in its acquisition of Allied Payment Network
Jetty National in its sale to Rhino Labs
Visible Body in its sale to Cengage Group
Repsly in its sale to Cuadrilla Capital
Demand Science in its sale to Terminus
Sheehan Family Companies in its recapitalization/sale transaction
Celsius Therapeutics in its $250 million sale transaction
Virtusa Corporation in its $2 billion sale to Baring Private Equity Asia
Bessemer Venture Partners in its acquisition of Litify
Apollo Intelligence Corporation in its acquisition of SurveyHealthcareGlobus and its sale to Frazier Healthcare
Surface Oncology in its sale to Coherus BioSciences
EQRx in its $1.8 billion business combination with CM Life Sciences III, a Special Purpose Acquisition Company (SPAC)
Roman DBDR Tech Acquisition Corp. (a SPAC) in its business combination with Composecure
Related Companies in its strategic partnership with HQO
Starburst Data in its acquisition of Varada
eVariant in its sale to Healthgrades
Stockholders of New England Treatment Access in its sale to Surterra Wellness

Royalty Pharma, a leading investor in pre-approval royalties, in its $827 million acquisition of Ligand’s royalties on sales of Promacta
Royalty Pharma in its up to $650 million acquisition of Vertex’s residual royalty interest in its cystic fibrosis treatments owned by the Cystic Fibrosis Foundation
Royalty Pharma in its $450 million acquisition of (i) a partial interest in Biohaven’s royalties on sales of zavegepant and (ii) preferred stock of Biohaven
Royalty Pharma in its $650 million acquisition of a partial interest in PTC’s royalties on sales of risdiplam
Chiasma in its $75 million royalty financing with HealthCare Royalty Partners

Areas of Practice

Professional Experience

Prior to joining Goodwin, Brett was an associate at a prominent international law firm in New York, where he was a member of the M&A and Securities Practice group.

Credentials

Education

JD2016

Fordham University School of Law

(magna cum laude)

MA2013

Trinity College

BA2009

Trinity College

Admissions

Bars

Massachusetts
New York

Recognition & Awards

Brett was recognized in Boston Magazine’s list of the “Top Lawyers of 2021.”

Brett Jackson

Representative Matters

Areas of Practice

Professional Experience

Credentials

Education

JD2016

MA2013

BA2009

Admissions

Bars

Recognition & Awards

Related Content

Goodwin Names 21 New Counsel

Goodwin Advises Suno on $250 Million Series C Financing at $2.45 Billion Valuation

Goodwin Represents Quavo Fraud & Disputes in Securing $300 Million Growth Investment from Spectrum Equity

Goodwin Advises Jetty on Merger with Rhino to Create the Largest Security Deposit Insurance Company in the Market

Goodwin Advises Visible Body on Acquisition by Cengage Group to Enhance Science Offerings

Goodwin Advises CardFlight on Growth Investment from WestView Capital Partners

Goodwin Advises Sheehan Family Companies in Major Recapitalization Transaction

Surface Oncology To Be Acquired By Coherus In Stock for Stock Transaction Valued At Up To $65 Million Plus Contingent Value Rights

Technology

Technology M&A

Mergers & Acquisitions

Brett Jackson

Representative Matters

Financings/General Corporate Counsel

Mergers and Acquisitions

Royalty-Based Financings

Capital Markets

Areas of Practice

Professional Experience

Credentials

Education

JD2016

MA2013

BA2009

Admissions

Bars

Recognition & Awards

Related Content

Goodwin Names 21 New Counsel

Goodwin Advises Suno on $250 Million Series C Financing at $2.45 Billion Valuation

Goodwin Represents Quavo Fraud & Disputes in Securing $300 Million Growth Investment from Spectrum Equity

Goodwin Advises Jetty on Merger with Rhino to Create the Largest Security Deposit Insurance Company in the Market

Goodwin Advises Visible Body on Acquisition by Cengage Group to Enhance Science Offerings

Goodwin Advises CardFlight on Growth Investment from WestView Capital Partners

Goodwin Advises Sheehan Family Companies in Major Recapitalization Transaction

Surface Oncology To Be Acquired By Coherus In Stock for Stock Transaction Valued At Up To $65 Million Plus Contingent Value Rights